TABLE 1.
General characteristics and follow‐up of the study population (N = 1000)
| Characteristics | Entire cohort (N = 1000) |
|---|---|
| Recipient characteristics at transplantation | |
| Age (y), mean ± SD (range) | 53.7 ± 13.3 (16.2‐82.6) |
| Recipient BMI at time of transplantation (kg/m2), mean ± SD (range) | 25.4 ± 4.5 (15.5‐42.0) |
| Sex (male), n (%) | 609 (60.9) |
| White, n (%) | 984 (98.4) |
| Repeat transplantation, n (%) | 154 (15.4) |
| Diabetes mellitus, n (%) | 166 (16.6) |
| Donor characteristics at transplantation | |
| Age (y), mean ± SD (range) | 47.7 ± 14.8 (5.2‐79.0) |
| Sex (male), n (%) | 535 (53.5) |
| Deceased donor, n (%) | 941 (94.1) |
| Donation after brain death, n (%) | 780 (78.0) |
| Transplant characteristics, treatment at transplantation and follow‐up | |
| Cold ischemia time (h), mean ± SD (range) | 14.2 ± 5.7 (0.17‐36.0) |
| Immunosuppression regimen: TAC‐MPA‐CS, n (%) | 874 (87.4) |
| Induction therapy, n (%) | 416 (41.6) |
| Basiliximab, n (%) | 355 (35.5) |
| Thymoglobulin, n (%) | 16 (1.6) |
| Other, n (%) | 45 (4.5) |
| Patients with anti‐HLA antibodies, n (%) | 262 (26.2) |
| HLA class I, n (%) | 94 (9.4) |
| HLA class II, n (%) | 60 (6.0) |
| HLA class I & II, n (%) | 104 (10.4) |
| Patients with DSA at LR level, n (%) | 140 (14.0) |
| Posttransplant data | |
| Follow‐up time (y), median (IQR) | 7.5 (4.9‐10.0) |
| Death‐censored graft survival | |
| At 1 y (%) | 95.2 |
| At 5 y (%) | 89.1 |
| At 10 y (%) | 80.7 |
Abbreviations: BMI, body mass index; CS, corticosteroids; DSA, donor‐specific anti‐HLA antibodies; HLA, human leukocyte antigen; IQR, interquartile range; LR, low‐resolution; MPA, mycophenolic acid; SD, standard deviation; TAC, tacrolimus.